Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp
Authors:
Open Access
- 31 March 2014
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (s2) , 10-21
Abstract
The fixed combination calcipotriol plus betamethasone dipropionate gel is a first‐line treatment for psoriasis vulgaris. The objective was to perform a large‐scale assessment of tolerability of fixed combination gel (Cal/BD). Analysis was performed on pooled 8‐week safety data from nine clinical trials evaluating once‐daily Cal/BD treatment of scalp (n = 6) and body (n = 3) psoriasis. Pharmacovigilance data were also assessed. Patients were treated with Cal/BD [n = 1953 (scalp), n = 824 (body)], betamethasone dipropionate gel (BD; n = 1214, n = 562), calcipotriol gel (Cal; n = 979, n = 175), gel vehicle (VEH; n = 173, n = 226), calcipotriol scalp solution [n = 104 (scalp only)] and tacalcitol ointment [TAC; n = 184 (body only)]. Most adverse events (AEs) were mild–moderate severity. The proportion of scalp psoriasis patients with ≥1 AE was lowest with Cal/BD (35% versus 38–57%). A similar proportion was found with Cal/BD for body psoriasis (32%), however, lower proportions were reported with BD (24%) and Cal (29%). The most common AEs with Cal/BD included nasopharyngitis, pruritus and upper respiratory tract infection (2–5% of patients). Overall, only 5% of patients treated with Cal/BD reported ≥1 lesional/perilesional AEs: the lowest incidence versus scalp comparators (6–19%) and second lowest to BD (3%) for body psoriasis. Similarly, Cal/BD treatment resulted in the lowest incidence of ≥1 adverse drug reactions (ADRs) in scalp psoriasis patients (8% versus 9–27%) and second lowest to BD (6% versus 4%) for body psoriasis. Overall, incidence of serious AEs (SAEs) was low (0–1%). Data received postmarketing through spontaneous reporting revealed that SAEs reported more than once with Cal/BD treatment were psoriasis (n = 5); and alopecia, erythrodermic psoriasis, pruritus, skin atrophy and urticaria (n = 2 each). In this large subset of patients treated with Cal/BD, incidence of AEs and ADRs is consistently low. This analysis provides further evidence of the good tolerability of the fixed combination gel as treatment for psoriasis vulgaris.Keywords
Funding Information
- LEO Pharma
This publication has 30 references indexed in Scilit:
- Calcipotriol/Betamethasone DipropionateDrugs, 2011
- A calcipotriene/betamethasone dipropionate two‐compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8‐week, double‐blind phase of a clinical trialInternational Journal of Dermatology, 2010
- Psoriasis: depression, anxiety, smoking, and drinking habitsDermatologic Therapy, 2010
- The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groupsHealth and Quality of Life Outcomes, 2009
- Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trialBritish Journal of Dermatology, 2009
- A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trialBritish Journal of Dermatology, 2009
- A Study of the Safety and Efficacy of Calcipotriol and Betamethasone Dipropionate Scalp Formulation in the Long-Term Management of Scalp PsoriasisDermatology, 2008
- Calcipotriol plus Betamethasone Dipropionate Scalp Formulation Is Effective and Well Tolerated in the Treatment of Scalp Psoriasis: A Phase II StudyDermatology, 2008
- Scalp psoriasis: a review of current topical treatment optionsJournal of the European Academy of Dermatology and Venereology, 2007
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007